Join our webinar on November 3rd at 3:00 pm (CET) to discover how AAX Biotech’s Opti-mAb® technology can address scFv instability and support the development of complex multispecific antibodies.
In this webinar, experts from AAX Biotech and evitria share new data on scFv-containing bi- and trispecific formats and discuss how the technology works alongside evitria’s CHO-based expression platform.
